Mechanistic Rationale and Clinical Evidence for the Efficacy of Proteasome Inhibitors against Indolent and Mantle Cell Lymphomas

Author： Paoluzzi Luca O'Connor Owen A.

Publisher： Adis International

ISSN： 1173-8804

Source： BioDrugs, Vol.20, Iss.1, 2006-01, pp. : 13-23

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Radioimmunotherapy for Indolent B-Cell Non-Hodgkin Lymphoma in Relapsed, Refractory and Transformed Disease

By Visser Otto J.

BioDrugs, Vol. 20, Iss. 4, 2006-01 ,pp. : 201-207

Adis International

Access to resources Recommend Favorite

Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia

By Ali Sharmila Binte Shamshad

International Journal of Evidence-based Healthcare, Vol. 11, Iss. 2, 2013-06 ,pp. : 145-146

Blackwell Publishing

Access to resources Recommend Favorite

Differentiating "Clinical Evidence" and "Clinical Knowledge"

By Dreher H. Michael

Clinical Scholars Review, Vol. 6, Iss. 1, 2013-04 ,pp. : 9-12

Springer Publishing Company

Access to resources Recommend Favorite

A Case with an Indolent Course of Subcutaneous Panniculitis-Like T-Cell Lymphoma Demonstrating Epstein-Barr Virus Positivity and Simulating Dermatitis Artefacta

By Soylu Seçil

American Journal of Clinical Dermatology, Vol. 11, Iss. 2, 2010-04 ,pp. : 147-150

Adis International

Access to resources Recommend Favorite

MLV/HIV-pseudotyped vectors: a new treatment option for cutaneous t cell lymphomas

By Thaler S. Burger A.M. Schulz T. Schnierle B.S.

Molecular Therapy, Vol. 8, Iss. 5, 2003-11 ,pp. : 756-761

Elsevier

Access to resources Recommend Favorite